Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma

Journal of Human Genetics

Volumn 61, Issue 2, 2016, Pages 109-118

  Fukumoto, Ichiro ^a   Kikkawa, Naoko ^a   Matsushita, Ryosuke ^b   Kato, Mayuko ^a   Kurozumi, Akira ^a   Nishikawa, Rika ^a   Goto, Yusuke ^a   Koshizuka, Keiichi ^a   Hanazawa, Toyoyuki ^a   Enokida, Hideki ^b   Nakagawa, Masayuki ^b   Okamoto, Yoshitaka ^a   Seki, Naohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LOXL2 PROTEIN; MICRORNA; MICRORNA 218; MICRORNA 26A; MICRORNA 26B; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; PROTEIN; UNCLASSIFIED DRUG; LOXL2 PROTEIN, HUMAN; MIRN218 MICRORNA, HUMAN; MIRN26A MICRORNA, HUMAN; MIRN29 MICRORNA, HUMAN; OXIDOREDUCTASE;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LUCIFERASE ASSAY; MALE; METASTASIS; MIDDLE AGED; OROPHARYNX CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TONGUE CARCINOMA; TUMOR INVASION; VERY ELDERLY; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

AMINO ACID OXIDOREDUCTASES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MICRORNAS;

EID: 84959280784     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2015.120     Document Type: Article

References (48)

1. Kulasinghe, A., Perry, C., Jovanovic, L., Nelson, C., & Punyadeera, C. Circulating tumour cells in metastatic head and neck cancers. Int. J. Cancer 136, 2515-2523 (2015)
2. Takes, R. P., Strojan, P., Silver, C. E., Bradley, P. J., Haigentz, M. Jr, Wolf, G. T., et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck 34, 270-281 (2012)
3. Chan, J. Y., & Wei, W. I. Current management strategy of hypopharyngeal carcinoma. Auris Nasus Larynx 40, 2-6 (2013)
4. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004)
5. Wiemer, E. A. The role of microRNAs in cancer: no small matter. Eur. J. Cancer 43, 1529-1544 (2007)
6. Singh, S. K., Pal Bhadra, M., Girschick, H. J., & Bhadra, U. MicroRNAs-micro in size but macro in function. FEBS J. 275, 4929-4944 (2008)
7. Iorio, M. V., & Croce, C. M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 27, 5848-5856 (2009)
8. Kikkawa, N., Hanazawa, T., Fujimura, L., Nohata, N., Suzuki, H., Chazono, H., et al. miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br. J. Cancer 103, 877-884 (2010)
9. Nohata, N., Hanazawa, T., Kikkawa, N., Sakurai, D., Fujimura, L., Chiyomaru, T., et al. Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. Br. J. Cancer 105, 833-841 (2011)
10. Fukumoto, I., Kinoshita, T., Hanazawa, T., Kikkawa, N., Chiyomaru, T., Enokida, H., et al. Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature. Br. J. Cancer 111, 386-394 (2014)
11. Fukumoto, I., Hanazawa, T., Kinoshita, T., Kikkawa, N., Koshizuka, K., Goto, Y., et al. MicroRNA expression signature of oral squamous cell carcinoma: functional role of microRNA-26a/b in the modulation of novel cancer pathways. Br. J. Cancer 112, 891-900 (2015)
12. Kinoshita, T., Hanazawa, T., Nohata, N., Kikkawa, N., Enokida, H., Yoshino, H., et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget. 3, 1386-1400 (2012)
13. Kinoshita, T., Nohata, N., Hanazawa, T., Kikkawa, N., Yamamoto, N., Yoshino, H., et al. Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br. J. Cancer 109, 2636-2645 (2013)
14. Kim, S. H., Turnbull, J., & Guimond, S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol. 209, 139-151 (2011)
15. Harisi, R., & Jeney, A. Extracellular matrix as target for antitumor therapy. Onco Targets Ther. 8, 1387-1398 (2015)
16. Ganguly, K. K., Pal, S., Moulik, S., & Chatterjee, A. Integrins and metastasis. Cell Adh. Migr. 7, 251-261 (2013)
17. Ding, S., Chen, G., Zhang, W., Xing, C., Xu, X., Xie, H., et al. MRC-5 fibroblastconditioned medium influences multiple pathways regulating invasion, migration, proliferation, and apoptosis in hepatocellular carcinoma. J. Transl. Med. 13, 237 (2015)
18. dos Santos, P. B., Zanetti, J. S., Ribeiro-Silva, A., & Beltrao, E. I. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn. Pathol. 7, 104 (2012)
19. Goc, A., Liu, J., Byzova, T. V., & Somanath, P. R. Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin beta(3) affinity modulation. Br. J. Cancer 107, 713-723 (2012)
20. Nishikawa, R., Goto, Y., Sakamoto, S., Chiyomaru, T., Enokida, H., Kojima, S., et al. Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci. 105, 802-811 (2014)
21. Nishikawa, R., Chiyomaru, T., Enokida, H., Inoguchi, S., Ishihara, T., Matsushita, R., et al. Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. FEBS Lett. 589, 2136-2145 (2015)
22. Yokota, S., Ogawara, K., Kimura, R., Shimizu, F., Baba, T., Minakawa, Y., et al. Protein O-fucosyltransferase 1: a potential diagnostic marker and therapeutic target for human oral cancer. Int. J. Oncol. 43, 1864-1870 (2013)
23. Zhuang, Z., Jian, P., Longjiang, L., Bo, H., & Wenlin, X. Oral v displayed distinct biologic behaviors and gene expression profiles. J. Oral Pathol. Med. 39, 168-175 (2010)
24. Chen, D., Cabay, R. J., Jin, Y., Wang, A., Lu, Y., Shah-Khan, M., et al. MicroRNA deregulations in head and neck squamous cell carcinomas. J. Oral Maxillofac. Res. 4, e2 (2013)
25. Janiszewska, J., Szaumkessel, M., & Szyfter, K. microRNAs are important players in head and neck carcinoma: a review. Crit. Rev. Oncol. Hematol. 88, 716-728 (2013)
26. Gao, J., & Liu, Q. G. The role of miR-26 in tumors and normal tissues (Review). Oncol. Lett. 2, 1019-1023 (2011)
27. Jiang, H., Zhang, G., Wu, J. H., & Jiang, C. P. Diverse roles of miR-29 in cancer (review). Oncol. Rep. 31, 1509-1516 (2014)
28. Tatarano, S., Chiyomaru, T., Kawakami, K., Enokida, H., Yoshino, H., Hidaka, H., et al. miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int. J. Oncol. 39, 13-21 (2011)
29. Lu, Y. F., Zhang, L., Waye, M. M., Fu, W. M., & Zhang, J. F. MiR-218 mediates tumorigenesis and metastasis: perspectives and implications. Exp. Cell Res. 334, 173-182 (2015)
30. Ahn, S. G., Dong, S. M., Oshima, A., Kim, W. H., Lee, H. M., Lee, S. A., et al. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Res. Treat. 141, 89-99 (2013)
31. Shih, Y. H., Chang, K. W., Chen, M. Y., Yu, C. C., Lin, D. J., Hsia, S. M., et al. Lysyl oxidase and enhancement of cell proliferation and angiogenesis in oral squamous cell carcinoma. Head Neck 35, 250-256 (2013)
32. Wong, C. C., Tse, A. P., Huang, Y. P., Zhu, Y. T., Chiu, D. K., Lai, R. K., et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology 60, 1645-1658 (2014)
33. Ruckert, F., Joensson, P., Saeger, H. D., Grutzmann, R., & Pilarsky, C. Functional analysis of LOXL2 in pancreatic carcinoma. Int. J. Colorectal Dis. 25, 303-311 (2010)
34. Barker, H. E., Cox, T. R., & Erler, J. T. The rationale for targeting the LOX family in cancer. Nat. Rev. Cancer 12, 540-552 (2012)
35. Guo, X., Wu, Y., Hathaway, H. J., & Hartley, R. S. Microenvironmental control of the breast cancer cell cycle. Anat. Rec. (Hoboken) 295, 553-562 (2012)
36. Haslene-Hox, H., Oveland, E., Woie, K., Salvesen, H. B., Tenstad, O., & Wiig, H. Distribution volumes of macromolecules in human ovarian and endometrial cancers-Effects of extracellular matrix structure. Am. J. Physiol. Heart Circ. Physiol. 308, H18-H28 (2015)
37. Iuliano, J. N., Kutscha, P. D., Biderman, N. J., Subbaram, S., Groves, T. R., Tenenbaum, S. A., et al. Metastatic bladder cancer cells distinctively sense and respond to physical cues of collagen fibril-mimetic nanotopography. Exp. Biol. Med. (Maywood) 240, 601-610 (2015)
38. Cano, A., Santamaria, P. G., & Moreno-Bueno, G. LOXL2 in epithelial cell plasticity and tumor progression. Future Oncol. 8, 1095-1108 (2012)
39. Schietke, R., Warnecke, C., Wacker, I., Schodel, J., Mole, D. R., Campean, V., et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J. Biol. Chem. 285, 6658-6669 (2010)
40. Gilkes, D. M., Semenza, G. L., & Wirtz, D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14, 430-439 (2014)
41. Sricholpech, M., Perdivara, I., Nagaoka, H., Yokoyama, M., Tomer, K. B., & Yamauchi, M. Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues in type I collagen in osteoblast culture. J. Biol. Chem. 286, 8846-8856 (2011)
42. Xiao, H. B., Liu, R. H., Ling, G. H., Xiao, L., Xia, Y. C., Liu, F. Y., et al. HSP47 regulates ECM accumulation in renal proximal tubular cells induced by TGF-beta1 through ERK1/2 and JNK MAPK pathways. Am. J. Physiol. Renal Physiol. 303, F757-F765 (2012)
43. Noel, A., Gutierrez-Fernandez, A., Sounni, N. E., Behrendt, N., Maquoi, E., Lund, I. K., et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol. 3, 140 (2012)
44. Diaz-Lopez, A., Moreno-Bueno, G., & Cano, A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag. Res. 6, 205-216 (2014)
45. Guo, F., Parker Kerrigan, B. C., Yang, D., Hu, L., Shmulevich, I., Sood, A. K., et al. Post-Transcriptional regulatory network of epithelial-To-mesenchymal and mesenchymalto-Epithelial transitions. J. Hematol. Oncol. 7, 19 (2014)
46. Moon, H. J., Finney, J., Ronnebaum, T., & Mure, M. Human lysyl oxidase-like 2. Bioorg. Chem. 57, 231-241 (2014)
47. Martin, A., Salvador, F., Moreno-Bueno, G., Floristan, A., Ruiz-Herguido, C., Cuevas, E. P., et al. Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression. EMBO J. 34, 1090-1109 (2015)
48. Sun, W., Gaykalova, D. A., Ochs, M. F., Mambo, E., Arnaoutakis, D., Liu, Y., et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 74, 1091-1104 (2014).